New resource models human metabolism
Scandinavian researchers have created a unified, open-source model providing a genome-wide portrait of human disease metabolism.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1324 entries already.
Entries by Thomas Gabrielczyk
Novacyt inks contract on Covid-19 diagnostics
/in News/by Thomas GabrielczykParis-based Novacyt SA has signed a global distribution agreement with Bruker Ltd for its COVID-19 diagnostic test.
AC Immune SA gets Lilly milestone for Alzheimers candidate
/in News/by Thomas GabrielczykAC Immune SA has received a milestone payment of CHF10m from Eli Lilly and Company.
Experts discuss link between sepsis and Covid-19
/in News/by Thomas GabrielczykScientists have discussed a link between Covid-19 and sepsis at a virtual symposium at Charité Berlin that might help reduce the burden of end-stage disease.
Evonik Industries AG establishes production of recombinant collagen
/in News/by Thomas GabrielczykEvonik Industries has established a new animal-free and fermentation-based industrial-scale recombinant collagen production platform.
BioNTech SEs COVID-19 vaccine attracts investment
/in News/by Thomas GabrielczykChinese Fosun Pharma Ltd has made the largest investment in a foreign company for a COVID-19 vaccine development: BioNTechd mRNA vaccine BNT162.
Commission relaunches circular economy action plan
/in News/by Thomas GabrielczykUnder its Green Deal, the European Commission has presented a circular (bio)economay action plan that prepares the ground for a sustainable bio-economy.
Roche unravel biomarker for checkpoint blockade
/in News/by Thomas GabrielczykResearchers at Swiss pharma giant Roche AG have found a subpopulation of dendritic cells to determine how cancer patients respond to immune checkpoint inhibitors.
Nutrition influences the course of MS
/in News/by Thomas GabrielczykNew data prove that propionic acid modulates the intestine-mediated immune regulation in people with multiple sclerosis (MS).
LSP launches US-$600m European life sciences fund
/in News/by Thomas GabrielczykLSP has closed its LSP 6 fund at the $600m hard cap. It is the largest fund ever raised in Europe focused on life sciences ventures.